Measurement of platelet-activating factor in human blood by high performance thin layer chromatography and its clinical application

Abstract

Platelet-activating factor (PAF) present in the blood of the patients with chronic pulmonary heart disease and asthma has been detected by high performance thin layer chromatography (HPTLC). The patients with chronic pulmonary heart disease accompanied by carbon dioxide retention (PaCO₂>6.67 kPa) have a higher level of PAF in blood (0. 75 ±0. 27 μg/ml) than those who have no carbon dioxide retention (PaCO₂<6.67 kPa, PAF 0.41 ±0. 25 μg/ml) and those in the normal control group (0.45 ±0.20 μg/ml), withP<0.05 in all. The patients with asthma have a higher PAF in blood (0.83±0. 05 μg/ml) than those in the control group (P < 0.005). These findings suggest that PAF plays an important role in episodes of chronic pulmonary heart disease and asthma.

Keywords

PAF (platelet-activating factor) / HPTLC (high performance thin layer chromatography)

References

[1] VillamedianaL M, et al.. Effects of the PAF antagonist of the liver. Life sciences, 1986, 39: 201-201

[2] BlighE G, DyerW J. A rapid of total lipid extraction and purification. Can J Biochem Physiol, 1959, 37: 911-911

[3] PinckardR N, et al.. Physiochemical and functional identity of rabbit PAF released in vitro from IgE sensitized basophils. J Immunology, 1979, 123(4): 1847-1847

[4] BornG V A, et al.. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature, 1962, 194: 927-927

[5] Crespo M Set al. Presence in normal human urine of a hypotensive and platelet-activating phospholipid. Am Physiol Society, 1983;F706

[6] BenvenisteJ, et al.. Structural analysis of purified PAF by lipase. Nature (lond), 1977, 269: 270-270